Your browser doesn't support javascript.
loading
Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations.
Botton, Jérémie; Semenzato, Laura; Jabagi, Marie-Joëlle; Baricault, Bérangère; Weill, Alain; Dray-Spira, Rosemary; Zureik, Mahmoud.
Afiliação
  • Botton J; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, Saint-Denis, France.
  • Semenzato L; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, Saint-Denis, France.
  • Jabagi MJ; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, Saint-Denis, France.
  • Baricault B; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, Saint-Denis, France.
  • Weill A; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, Saint-Denis, France.
  • Dray-Spira R; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, Saint-Denis, France.
  • Zureik M; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, Saint-Denis, France.
JAMA Netw Open ; 5(3): e220868, 2022 03 01.
Article em En | MEDLINE | ID: mdl-35234883
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Eficácia de Vacinas / Vacina BNT162 / Ad26COVS1 / Hospitalização Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Eficácia de Vacinas / Vacina BNT162 / Ad26COVS1 / Hospitalização Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article